Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 07, 2023

BUY
$6.71 - $11.83 $152,317 - $268,541
22,700 Added 1194.74%
24,600 $165,000
Q2 2023

Aug 08, 2023

BUY
$11.12 - $22.2 $15,567 - $31,080
1,400 Added 280.0%
1,900 $21,000
Q1 2023

May 12, 2023

SELL
$18.7 - $23.07 $91,630 - $113,043
-4,900 Reduced 90.74%
500 $10,000
Q4 2022

Feb 13, 2023

SELL
$18.12 - $27.32 $3,714 - $5,600
-205 Reduced 3.66%
5,400 $122,000
Q3 2022

Nov 07, 2022

SELL
$16.98 - $25.54 $187,934 - $282,676
-11,068 Reduced 66.38%
5,605 $105,000
Q2 2022

Aug 09, 2022

BUY
$13.15 - $20.45 $219,249 - $340,962
16,673 New
16,673 $310,000
Q3 2021

Nov 09, 2021

SELL
$26.01 - $38.22 $8,713 - $12,803
-335 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$29.97 - $37.17 $10,039 - $12,451
335 New
335 $10,000
Q1 2021

May 14, 2021

SELL
$29.24 - $42.03 $5,906 - $8,490
-202 Closed
0 $0
Q4 2020

Feb 12, 2021

SELL
$35.35 - $50.67 $50,691 - $72,660
-1,434 Reduced 87.65%
202 $7,000
Q3 2020

Nov 16, 2020

BUY
$35.98 - $47.66 $36,231 - $47,993
1,007 Added 160.1%
1,636 $60,000
Q2 2020

Aug 13, 2020

BUY
$45.06 - $67.74 $11,084 - $16,664
246 Added 64.23%
629 $28,000
Q1 2020

May 13, 2020

BUY
$40.01 - $73.97 $15,323 - $28,330
383 New
383 $18,000
Q4 2019

Feb 10, 2020

SELL
$37.13 - $74.62 $37,130 - $74,620
-1,000 Closed
0 $0
Q3 2019

Nov 12, 2019

BUY
$39.36 - $76.8 $39,360 - $76,800
1,000 New
1,000 $39,000
Q4 2018

Feb 13, 2019

SELL
$22.8 - $33.93 $30,506 - $45,398
-1,338 Closed
0 $0
Q3 2018

Nov 13, 2018

SELL
$29.75 - $43.08 $178 - $258
-6 Reduced 0.45%
1,338 $48,000
Q2 2018

Aug 13, 2018

SELL
$21.96 - $39.94 $91,221 - $165,910
-4,154 Reduced 75.55%
1,344 $50,000
Q1 2018

May 11, 2018

BUY
$17.1 - $26.61 $91,707 - $142,709
5,363 Added 3972.59%
5,498 $129,000
Q4 2017

Feb 12, 2018

BUY
$9.47 - $19.59 $1,278 - $2,644
135
135 $2,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $657M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Quantbot Technologies LP Portfolio

Follow Quantbot Technologies LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

News

Stay updated on Quantbot Technologies LP with notifications on news.